In its first results since its insurance unit CEO was fatally shot in New York City, UnitedHealth Group reported Thursday weaker-than-expected fourth-quarter revenue, prompting its shares to fall in early morning trading despite quarterly profit beating projections.

The UnitedHealth Group leader whose murder in December unleashed a torrent of public frustration and dissatisfaction with the U.S. health care system was pushing for some of the very improvements that critics have been seeking.

UnitedHealth Group reported bottom-line earnings that surpassed estimates despite regulatory challenges impacting revenue.

This was the stock's second consecutive day of gains.

UnitedHealth posted a better-than-expected profit in the final quarter of 2024, but revenue fell short as challenges like Medicare funding cuts and a Medicaid enrollment drop hurt. Shares of the health care giant slid early Thursday after it released its first financial report since the brazen shooting of one of its executives outside a New York City hotel touched a national nerve and brought to the surface American frustration over health care access.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The stock's fall snapped a four-day winning streak.

The company is at a pivotal point following the killing of Brian Thompson, who headed the UnitedHealthcare unit, and there was a public outcry about insurance denials. That prompted Andrew Witty, the chief executive of all of UnitedHealth, to write of a need "to improve how we explain what insurance covers and how decisions are made."

UnitedHealth shares have been pressured recently, falling about 10% since Dec. 4, when Thompson was killed. That outpaces the 3% drop in the S&P 500 index over that span and signals some investor jitters about the future of the business.

B, consensus $445.64B. The company said, “UnitedHealth Group affirmed the 2025 performance outlook established in December 2024, including reve

The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.